Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $92

Author: Benzinga Newsdesk | March 18, 2024 07:57am
JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $88 to $92.

Posted In: RARE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist